[Abstract Title]. - Society for Neuroscience

(2006) exhibited lower pain ratings. This relationship was particularly striking for rs4411417 (p
= .005). For this SNP, those having the common variant reported 77% more pain than those
exhibiting the uncommon allele. Significant effects were also evident for rs3783641, and
rs752688 (p‟s < 0.05). When combined, these three SNPs accounted for a surprisingly high 35%
of the inter-individual variance in pain ratings. We conclude that SNPs of the GCH1 gene
powerfully affect ratings of pain induced by capsaicin.
Disclosures: C. Campbell, None; J.N. Campbell , Jim Campbell has an employment
arrangement with InterWest Partners, which in turn has an investment in Solace Pharmaceuticals,
which in turn has a development program related to GCH1., A. Employment (full or parttime);
R. Edwards, None; C. Carmona, None; M. Uhart, None; G. Wand, None; A. Carteret,
None; J. Frost, None; Y. Kim, None.
Poster
266. Pain: Psychophysics and Behavior
Time: Sunday, November 16, 2008, 1:00 pm - 5:00 pm
Program#/Poster#: 266.5/EE27
Topic: D.08.h. Psychophysics and behavior
Support: NIH NS04406
Title: Persistence of chemo-neuropathy related pain and sensory dysfunction at long-term reexamination
Authors: *P. M. DOUGHERTY, A. W. BURTON, B. HAMID, L. C. DRIVER, H.-R. WENG;
Div. Anesthesiol & Critical Care Med., Univ. Texas, Anderson Cancer Inst., Houston, TX
Abstract: Neuropathic pain is one of the chief dose-limiting toxicities associated with each of
the major cancer chemotherapeutic drugs. Previous reports have shown pronounced sensory
deficits, both within and in surrounding areas, of on-going pain in patients with chronic
chemotherapy-related pain. Here we report pain ratings, analgesic use, and quantitative sensory
findings obtained from patients with chronic chemo-neuropathy at a one-year or greater followup
re-re-examination. Patients completed pain diagrams, selection of word descriptors, pain
medication history inventories and then underwent a repeat quantitative sensory examination to
assess touch (Aβ), sharpness (Aδ) and heat pain (C-fiber) sensibility. The results show that all
indices, except daily maximum pain, remain unchanged over the follow-up interval for all
patients that originally entered the study with chemotherapy-related pain of greater than 3
months duration. Daily maximum pain ratings were modestly reduced. These results indicate that
chemotherapy-related neuropathy is both very persistent and also refractory to therapy once the